Roche reported two Phase 3 victories for its BTK inhibitor in multiple sclerosis, clearing the primary objectives in separate registrational studies. One trial showed non-inferiority to established therapy, while the companion study delivered the targeted clinical endpoints across relapsing and progressive MS cohorts. The twin wins mark a surprising turnaround for the BTK class after prior late-stage setbacks by rivals. Roche will now evaluate regulatory paths toward submission; the data strengthen the company’s oral neuroimmunology portfolio and could expand treatment options for diverse MS subtypes.